Issue link: https://viewer.e-digitaledition.com/i/1080513
CONTINUED FROM PAGE 8 SCIENCE SNPs DETECTING ALZHEIMER'S DISEASE EARLIER Cerebral amyloid angiopathy (CAA) is the buildup of amyloid proteins in the blood vessels of the brain, which, along with amyloid plaques, constitutes one of the major hallmarks of the brain pathology of Alzheimer's disease. Due to their extra copy of chromosome 21, on which the amyloid gene resides, people with Down syndrome develop amyloid deposits by ages 30 –40, and most, but not all, develop dementia by ages 50 –60. Microbleeds in the brain and cortical superficial siderosis (a condition in which iron-rich blood byproducts get deposited in the brain) have emerged as two notable biomarkers of CAA. Researchers in Italy and Germany recently learned they could detect these CAA biomarkers in children with Down syndrome as young as 5 years old simply by using highly sensitive MRI imaging. This discovery could potentially lead to early interventions and preventive therapies at younger ages. Schoeppe, et al. European Journal of Paediatric Neurology, 2018. pii: S1090-3798(17)31945-1. A POSSIBLE NEW THERAPY FOR LOW BONE DENSITY People with Down syndrome frequently experience low bone mineral density, which can lead to osteoporosis and life-limiting fractures. Medications used in the typical population can be ineffective in people with Down syndrome, due to their unique bone mass phenotype. Researchers from Texas A&M University and the University of Arkansas for Medical Sciences found that a therapy called sclerostin antibody increased bone mass in a mouse model of Down syndrome (Ts65Dn) to levels equal to those of age-matched mouse models without Down syndrome. The therapy works by suppressing sclerostin, which interferes with bone formation. The researchers suggest the therapy in mouse models could someday help people with Down syndrome avoid debilitating bone fractures. Williams, et al. JBMR Plus ® . 2017;2(1):47-54. had no idea that the science would be so fascinating and that I would come to feel that people with Down syndrome are like my extended family." Three years later, Dr. Espinosa and his team discovered that the extra copy of chromosome 21 in people with Down syndrome triggers an immune system process called the interferon response, which may have a significant bearing on cancer risk. "From birth, the immune system of people with Down syndrome is very dysregulated," Dr. Espinosa says. "It's out of balance, so aspects of it are hyperactive and others are weakened. The hyperactivity may explain why solid tumor cancers are not allowed to grow and, therefore, why it is rare for people with Down syndrome to get most solid tumor cancers. Conversely, it may also explain why autoimmune disorders are so prevalent." Other researchers hypothesize that chromosome 21 contains one or more tumor-suppressing genes, which may explain why having an extra copy of the chromosome protects against solid tumors, and that the chromosome also contains genes that spur the development of leukemias. LEUKEMIA: AN EARLY CHILDHOOD RISK Children with Down syndrome are particularly susceptible to two types of leukemia: acute megakaryoblastic leukemia (AMKL) and B-cell acute lymphoblastic leukemia (B-ALL), the most common subtype of acute lymphoblastic leukemia (ALL). They are also uniquely susceptible to one bone marrow disorder that results in a higher risk of AMKL called transient myeloproliferative disorder (TMD). TMD, also called transient leukemia, is found only in newborns with Down syndrome. As many as 30 percent of babies with Down syndrome are born with TMD, and although it can cause severe or life-threatening problems, the overwhelming majority of cases resolve naturally by the third month of life. However, infants with TMD are at increased risk of developing acute myeloid leukemia (AML), which can strike children all the way through the teenage years. In particular, children with Down syndrome between ages 1 and 5 are 150 times more likely than typical children to develop AMKL, a rare type of AML. AMKL is a life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally and injure various tissues. While the risk for AMKL is considerably higher, many studies report better outcomes for patients with Down syndrome compared with their typical counterparts. Children with Down syndrome who develop AMKL have a roughly 80 percent five- year event-free survival rate, which is substantially better than that seen in typical children with this leukemia, according to John Crispino, Ph.D., Robert I. Lurie, M.D. and Lora S. Lurie Professor of Medicine at Northwestern University. "Nevertheless, not all children with Down syndrome survive the disease, and survival rates for those who relapse even after a bone marrow transplant are abysmal," Dr. Crispino says. Dr. Crispino's lab has several areas of focus including acute leukemias and myeloproliferative neoplasms, and he is considered 2018 ISSUE 4 OF 4 • DOWN SYNDROME WORLD ™ 10

